Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
Adenocarcinoma
/ drug therapy
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bevacizumab
/ therapeutic use
Colorectal Neoplasms
/ drug therapy
Disease-Free Survival
Drug Combinations
Female
Humans
Male
Middle Aged
Neoplasm Metastasis
Pyrrolidines
/ therapeutic use
Retrospective Studies
Thymine
Trifluridine
/ therapeutic use
Uracil
/ analogs & derivatives
Young Adult
Lonsurf
TAS-102
Trifluridine/tipiracil plus bevacizumab
mCRC
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
27 Dec 2019
27 Dec 2019
Historique:
received:
24
08
2019
accepted:
17
12
2019
entrez:
29
12
2019
pubmed:
29
12
2019
medline:
8
5
2020
Statut:
epublish
Résumé
A previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile. This retrospective study aimed to investigate the safety and efficacy of trifluridine/tipiracil plus bevacizumab compared with trifluridine/tipiracil monotherapy in patients with heavily pretreated mCRC in clinical settings. Records of patients with mCRC refractory to standard therapies who initiated trifluridine/tipiracil plus bevacizumab from January 2016 to March 2018 or trifluridine/tipiracil monotherapy from June 2014 to December 2015 were retrospectively reviewed at our institution. Totally, 60 patients received trifluridine/tipiracil plus bevacizumab and 66 received trifluridine/tipiracil monotherapy. All patients had previously received standard chemotherapy. Median progression-free survival (PFS) was 3.7 months [95% confidence interval (CI), 2.3-5.1] in the trifluridine/tipiracil plus bevacizumab group and 2.2 months (95% CI, 1.8-2.6) in the trifluridine/tipiracil monotherapy group [hazards ratio (HR) 0.69; 95% CI 0.48-0.99]. PFS rate at 16 weeks was 46.6% for the trifluridine/tipiracil plus bevacizumab group and 33.9% for the trifluridine/tipiracil monotherapy group. Although a relatively higher incidence of grade ≥ 3 neutropenia was observed in the trifluridine/tipiracil plus bevacizumab group than that in the other group (50.0% vs. 40.9%, p = 0.371), the incidence of febrile neutropenia was not high (3.3% vs. 7.8%, p = 0.444). In real-world settings, trifluridine/tipiracil plus bevacizumab prolonged PFS and helped achieve higher 16-week PFS rate compared with trifluridine/tipiracil monotherapy in patients with heavily pretreated mCRC with manageable toxicities. Retrospectively registered.
Sections du résumé
BACKGROUND
BACKGROUND
A previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile. This retrospective study aimed to investigate the safety and efficacy of trifluridine/tipiracil plus bevacizumab compared with trifluridine/tipiracil monotherapy in patients with heavily pretreated mCRC in clinical settings.
METHODS
METHODS
Records of patients with mCRC refractory to standard therapies who initiated trifluridine/tipiracil plus bevacizumab from January 2016 to March 2018 or trifluridine/tipiracil monotherapy from June 2014 to December 2015 were retrospectively reviewed at our institution.
RESULTS
RESULTS
Totally, 60 patients received trifluridine/tipiracil plus bevacizumab and 66 received trifluridine/tipiracil monotherapy. All patients had previously received standard chemotherapy. Median progression-free survival (PFS) was 3.7 months [95% confidence interval (CI), 2.3-5.1] in the trifluridine/tipiracil plus bevacizumab group and 2.2 months (95% CI, 1.8-2.6) in the trifluridine/tipiracil monotherapy group [hazards ratio (HR) 0.69; 95% CI 0.48-0.99]. PFS rate at 16 weeks was 46.6% for the trifluridine/tipiracil plus bevacizumab group and 33.9% for the trifluridine/tipiracil monotherapy group. Although a relatively higher incidence of grade ≥ 3 neutropenia was observed in the trifluridine/tipiracil plus bevacizumab group than that in the other group (50.0% vs. 40.9%, p = 0.371), the incidence of febrile neutropenia was not high (3.3% vs. 7.8%, p = 0.444).
CONCLUSIONS
CONCLUSIONS
In real-world settings, trifluridine/tipiracil plus bevacizumab prolonged PFS and helped achieve higher 16-week PFS rate compared with trifluridine/tipiracil monotherapy in patients with heavily pretreated mCRC with manageable toxicities.
TRIAL REGISTRATION
BACKGROUND
Retrospectively registered.
Identifiants
pubmed: 31881856
doi: 10.1186/s12885-019-6475-6
pii: 10.1186/s12885-019-6475-6
pmc: PMC6935149
doi:
Substances chimiques
Drug Combinations
0
Pyrrolidines
0
trifluridine tipiracil drug combination
0
Bevacizumab
2S9ZZM9Q9V
Uracil
56HH86ZVCT
Thymine
QR26YLT7LT
Trifluridine
RMW9V5RW38
Types de publication
Clinical Trial
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1253Références
ESMO Open. 2018 Aug 16;3(5):e000411
pubmed: 30167332
JAMA. 2017 Jun 20;317(23):2392-2401
pubmed: 28632865
Lancet Oncol. 2012 Oct;13(10):993-1001
pubmed: 22951287
J Clin Oncol. 2018 Feb 1;36(4):350-358
pubmed: 29215955
Lancet Oncol. 2014 Sep;15(10):1065-75
pubmed: 25088940
Lancet. 2013 Jan 26;381(9863):303-12
pubmed: 23177514
Lancet Oncol. 2015 May;16(5):499-508
pubmed: 25877855
J Clin Oncol. 2012 Oct 1;30(28):3499-506
pubmed: 22949147
Lancet Oncol. 2017 Sep;18(9):1172-1181
pubmed: 28760399
Clin Colorectal Cancer. 2016 Sep;15(3):e109-15
pubmed: 26723516
Oncol Rep. 2015 May;33(5):2135-42
pubmed: 25812794
N Engl J Med. 2015 May 14;372(20):1909-19
pubmed: 25970050